Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer
How this was made
The 30-second read
Why it matters
The webcast announcement provides the first public cue about upcoming trial data, which could move the stock if results are compelling.
Market read
The news is a primary disclosure that may attract speculative interest ahead of the data release.
What to watch
The trials are early‑stage with small patient numbers; any negative signal could quickly reverse any upside.
Background
Nkarta is a clinical‑stage biotech developing off‑the‑shelf CAR‑NK cell therapies for autoimmune diseases.
Ticker impact
Nkarta announced a webcast on Nov 9 to present initial clinical data for its NKX019 CAR‑NK cell therapy in autoimmune diseases.
possible modest upside as investors price in potential positive trial results
Webcast disclosure is new information; market typically reacts to early data cues, but actual impact depends on trial outcomes.
Market effects
Positive data could boost the broader biotech/autoimmune therapy sector.
Limited to US‑listed biotech investors.
Minor; primarily affects niche cell‑therapy investors.
Counterpoint
Investors may wait for actual data rather than trade on the announcement alone.
Key entities
- companyNkarta, Inc.
Developer of NKX019 CAR‑NK cell therapy.

